Presentation on different technologies to assess the impact of IMM-101 on the immune system in the approved phase 3 clinical trial for COVID-19 in cancer patients
Uxbridge, UK – 4th August 2020 – Immodulon, the Immuno-oncology company, today announces that a presentation discussing and evaluating different assay technologies to analyse the cellular and humoral components of the innate and adaptive immune system during an upcoming randomised, phase 3 study (“COV-IMMUNO” (NCT04442048), organised and sponsored by the Canadian Cancer Trials Group (CCTG), and supported by Immodulon), is being presented at the upcoming International Society for Advancement of Cytometry (ISAC) CYTO Virtual 2020 conference, 4-5 August 2020. It will be part of the Special Plenary Session 3: Biomarkers in Drug Development 3:00 – 5:00 PM (https://learning.isac-net.org/cytovirtual2020-day-2). This phase 3 study, approved by Health Canada, is designed to evaluate immunisation with the immunomodulator IMM-101 for the prevention of COVID-19 related infections and severe respiratory infections in cancer patients at increased risk of exposure.
The presentation, titled “Novel immunomodulators and their combinations require a broad, adaptive clinical biomarker strategy” will be presented by Dr Thomas Kleen, Chief Scientific Officer of Immodulon at 3:00 PM EDT (GMT-4) on 5 August. The presentation will discuss translational biomarker considerations for the CCTG sponsored COV-IMMUNO phase 3 study. Novel immunomodulators like IMM-101 require a broad, adaptive clinical biomarker strategy. The comprehensive immune monitoring strategy of cellular and humoral components of the innate and adaptive immune system that are important and the technologies and assays under considerations by the CCTG team for measuring innate and adaptive immune effects of IMM-101 during the COV-IMMUNO study in cancer patients will be outlined.
Dr. Jaap Kampinga, Chief Executive Officer of Immodulon, commented: “We are excited about the different advanced assay technologies and the translational biomarker monitoring strategy the CCTG team has developed, to measure the response of the immune system during the randomised, phase 3 study for COVID-19 in cancer patients. The hope is that through the detailed analysis of the effects on the immune system following IMM-101 administration the CCTG team can generate important, informative data for the current study and that these data forms a solid basis for adaptations and improvements in treatment protocols for future trials against cancers and viral infections such as COVID-19. Our lead drug candidate, IMM‑101, has been shown to activate those specific parts of the immune system that are generally thought to be required to effectively combat viral infections, and the CCTG team’s trial commencing this summer could provide important insights to the field.”